- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | XUANZHUBIO-B Phase III Clinical Study Data of Annerrazole Sodium for Reflux Esophagitis Presented at UEG Week 2026 | 2 | AASTOCKS | ||
| Mi | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT PHASE III CLINICAL STUDY DATA OF ANAPRAZOLE SODIUM FOR REFLUX ESOPHAGITIS PRESENTED AT UEG WEEK 2026PRESENTED ... | 2 | HKEx | ||
| 17.09. | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE MOVEMENTS | 1 | HKEx | ||
| 16.09. | XUANZHUBIO-B (02575): 2025 ANNUAL REPORT - SUPPLEMENTAL INFORMATION | 2 | HKEx | ||
| 16.09. | XUANZHUBIO-B (02575): 2026 INTERIM REPORT | 1 | HKEx | ||
| XUANZHU BIOPHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 03.09. | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT COMMERCIAL COOPERATION WITH INNOBIC FOR BIREOCICLIB IN THE THAILAND MARKET | 3 | HKEx | ||
| 26.08. | XUANZHUBIO-B (02575): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 13.08. | XUANZHUBIO-B (02575): DATE OF BOARD MEETING | - | HKEx | ||
| 30.06. | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT NDA ACCEPTED BY NMPA FOR THE NEW INDICATION OF ANAPRAZOLE SODIUM FOR THE TREATMENT OF REFLUX ESOPHAGITIS | 3 | HKEx | ||
| 18.06. | XUANZHUBIO-B (02575): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | - | HKEx | ||
| 18.06. | XUANZHUBIO-B (02575): ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR | 1 | HKEx | ||
| 18.06. | XUANZHUBIO-B (02575): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 18.06. | XUANZHUBIO-B (02575): POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING AND ABOLISHMENT OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| 27.05. | XUANZHUBIO-B (02575): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING | 3 | HKEx | ||
| 27.05. | XUANZHUBIO-B (02575): NOTICE OF THE 2025 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 27.05. | XUANZHUBIO-B (02575): CIRCULAR FOR THE 2025 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 26.05. | XUANZHUBIO-B (02575): PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION, ABOLITION OF THE SUPERVISORY COMMITTEE AND CHANGE OF BOARD COMPOSITION | - | HKEx | ||
| 12.05. | XUANZHUBIO-B (02575): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 12.05. | XUANZHUBIO-B (02575): INSIDE INFORMATION COMPLETION OF THE H SHARE FULL CIRCULATION BY THE COMPANY | 1 | HKEx | ||
| 27.04. | XUANZHUBIO-B (02575): LETTER TO NON-REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS ... | 2 | HKEx |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,050 | +0,26 % | Qiagen sorgt für Wirbel: 10,8-Milliarden-Deal begeistert Anleger | Der Diagnostikspezialist Qiagen steht vor einer milliardenschweren Übernahme und sorgt damit für Begeisterung an der Börse. Der schwedische Finanzinvestor EQT bietet 46,50 Euro je Aktie und bewertet... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,360 | +0,09 % | Wedbush raises Tango Therapeutics stock price target on trial data | ||
| COGENT BIOSCIENCES | 31,210 | 0,00 % | If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today | ||
| SUMMIT THERAPEUTICS | 15,470 | 0,00 % | Akeso, Inc.: Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer | Becomes the 7th International Registrational Clinical Trial for Ivonescimab
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026
HONG... ► Artikel lesen | |
| MODERNA | 178,42 | -0,19 % | Sell the News: Warum starke Studiendaten den Moderna-Kurs crashen lassen | Die Moderna-Aktie stürzt trotz starker Studiendaten zum Krebsimpfstoff mit Merck um mehr als 25 Prozent ab. Analysten sehen eine klassische Sell-the-News-Reaktion nach monatelanger Kursrallye. Die Moderna-Aktie... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 76,73 | 0,00 % | AstraZeneca, Cardiol Therapeutics, Kiniksa - Neue Hoffnung für Herzpatienten | Herz-Kreislauf-Erkrankungen gehören weltweit zu den größten medizinischen Herausforderungen. Während etablierte Pharmakonzerne Milliarden in neue Wirkstoffe und Künstliche Intelligenz investieren, entwickeln... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 27,200 | 0,00 % | Biotech Stocks At 52-Week Highs - Amylyx Pharmaceuticals +63% With Phase 3 Data, Vogenx +25%, Orchestra BioMed +19%, AtriCure, Charles River Laboratories | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 18, 2026, primarily driven by positive quarterly reports.Amylyx Pharmaceuticals Inc. (AMLX)Amylyx Pharmaceuticals... ► Artikel lesen | |
| LYCIA THERAPEUTICS | 29,560 | -1,47 % | Lycia Therapeutics Prices Upsized $317.5 Mln IPO At $18/Share | WASHINGTON (dpa-AFX) - Lycia Therapeutics Inc. (LYCA) a clinical-stage biotechnology company developing treatments for autoimmune, inflammatory, and allergic diseases, said Thursday it priced... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 41,520 | 0,00 % | H.C. Wainwright hebt Kursziel für Enliven Therapeutics auf 73 $ an | ||
| PRAXIS PRECISION MEDICINES | 252,88 | -0,03 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 21,010 | +0,05 % | ArriVent to present phase 1 data for ARR-217 at ESMO | ||
| BOLT BIOTHERAPEUTICS | 6,250 | -0,32 % | Bolt Biotherapeutics, Inc. - 8-K, Current Report | ||
| TRAVERE THERAPEUTICS | 50,05 | 0,00 % | Biotech Stocks At 52-Week Highs - Bioventus, Travere Therapeutics, Odyssey Therapeutics, Charles River Laboratories Climb With Q2 Results, Aclaris Therapeutics | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 5, 2026, primarily driven by positive quarterly reports.Bioventus Inc. (BVS)Bioventus is a medical device... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,100 | -0,08 % | Harmony Biosciences: Mizuho bekräftigt Einstufung nach Verhandlungen im Patentrechtsstreit | ||
| RECURSION PHARMACEUTICALS | 3,695 | -0,14 % | Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast |
XUANZHU BIOPHARMACEUTICAL CO LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,915 Euro und damit +0,33 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XUANZHU BIOPHARMACEUTICAL CO LTD finden Sie auf Wallstreet Online.